
Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.

Ash 2021 – Forma takes on a second Agios drug
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.

Ash 2021 – Global Blood stems the bleeding
The company reports decent data with its Oxbryta follow-on, but still has much to prove.

Ash 2021 – Agios and Forma take different paths in sickle cell disease
Forma still hopes for accelerated approval of etavopivat, while Agios believes that taking its time with mitapivat will pay off.

EHA 2021 movers – more fallers than risers
Protagonist and Autolus rose on Friday, but there were losses for Curis, Aptose, Forma and Equillium, among others.

Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.

Agios strengthens the case for mitapivat
A filing in pyruvate kinase deficiency beckons, but bigger indications could be trickier.